公开(公告)号：US11292843B2

公开(公告)日：2022-04-05

申请号：US16885067

申请日：2020-05-27

Applicant: Genentech, Inc.

Inventor： Doris Kim ,  Terence Wong ,  Anan Chuntharapai ,  Cherie Louise Green

IPC: C07K16/28 ,  G01N33/574

Abstract: The present application relates to anti-PD-L1 antibodies and their use to detect PD-L1 in a sample from a subject. In some embodiments, the subject has been treated with a therapeutic anti-PD-L1 antibody and an anti-PD-L1 described herein does not compete for binding to PD-L1 with the therapeutic anti-PD-L1 antibody. In some embodiments, the anti-PD-L1 antibody is linked to a N detectable moiety, such as a fluorophore and the anti-PD-L1 antibody is used to detect PD-L1 in a subject using flow cytometry.

公开(公告)号：US20140004038A1

公开(公告)日：2014-01-02

申请号：US13708761

申请日：2012-12-07

Applicant: Genentech, Inc.

Inventor： Anan Chuntharapai ,  Gregory D. Plowman ,  Marc Tessier-Lavigne ,  Yan Wu ,  Weilan Ye

IPC: A61K39/395 ,  A61K45/06 ,  A61K51/10

CPC classification number: A61K39/3955 ,  A61K45/06 ,  A61K51/1093 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/22 ,  C07K16/2842 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/74

Abstract: The present invention relates to the use of VEGF antagonists and alpha5beta1 antagonists for treating cancer and inhibiting angiogenesis and/or vascular permeability, including inhibiting abnormal angiogenesis in diseases. The present invention also relates to use of a VEGFR agonists and alpha5beta1 agonists to promote angiogenesis and vascular permeability. The present invention also relates to new anti-alpha5beta1 antibodies, compositions and kits comprising them and methods of making and using them.

Abstract translation: 本发明涉及VEGF拮抗剂和α5β1拮抗剂用于治疗癌症并抑制血管生成和/或血管通透性的用途，包括抑制疾病中的异常血管发生。 本发明还涉及VEGFR激动剂和α5β1激动剂促进血管生成和血管通透性的用途。 本发明还涉及新的抗α5β1抗体，包含它们的组合物和试剂盒以及制备和使用它们的方法。

公开(公告)号：US20230052312A1

公开(公告)日：2023-02-16

申请号：US17673648

申请日：2022-02-16

Applicant: Genentech, Inc.

Inventor： Doris KIM ,  Terence Wong ,  Anan Chuntharapai ,  Cherie Louise Green

IPC: G01N33/68 ,  G01N21/64 ,  G01N15/14 ,  G01N33/574 ,  C07K16/28

Abstract: The present application relates to anti-PD-L1 antibodies and their use to detect PD-L1 in a sample from a subject. In some embodiments, the subject has been treated with a therapeutic anti-PD-L1 antibody and an anti-PD-L1 described herein does not compete for binding to PD-L1 with the therapeutic anti-PD-L1 antibody. In some embodiments, the anti-PD-L1 antibody is linked to a detectable moiety, such as a fluorophore and the anti-PD-L1 antibody is used to detect PD-L1 in a subject using flow cytometry.

公开(公告)号：US20140115729A1

公开(公告)日：2014-04-24

申请号：US14137927

申请日：2013-12-20

Applicant: Genentech, Inc.

Inventor： Lawren Wu ,  Mercedesz Balazs ,  Hans Brightbill ,  Andrew Chan ,  Yvonne Chen ,  Anan Chuntharapai ,  Mark Dennis ,  Terence Wong

IPC: C07K16/42

CPC classification number: C07K16/4291 ,  A01K67/0278 ,  A01K2217/072 ,  A01K2227/105 ,  A01K2267/0387 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/73

Abstract: The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders.

Abstract translation: 本申请涉及凋亡性抗IgE抗体，编码它的核酸，其治疗组合物及其在治疗IgE介导的病症中的用途。